Please login to the form below

Not currently logged in

FDA rejects Transcept's insomnia drug

The US Food and Drug Administration has told Transcept Pharmaceuticals its insomnia drug, Intermezzo, is not ready for marketing approval

The US Food and Drug Administration (FDA) has told Transcept Pharmaceuticals its insomnia drug, Intermezzo (zolpidem tartrate sublingual tablet), is still not ready for marketing approval after the company sent a second new drug application (NDA).

Prior to issuing a complete response letter (expected July 14), the agency held a teleconference with Transcept expressing continued concerns about the safety profile of the drug based on information provided by the company.

It is Transcept's intention that Intermezzo be used for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.

The company said: "After the complete response letter is received, Transcept will announce additional information on the content of the letter and the company's plans forthe future regulatory development of Intermezzo."

According to the Wall Street Journal, shares of Transcept were down 41 per cent at $5.11 in recent premarket trading.

13th July 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....